New "Camera Pill” Locates Disease in Small Intestine

A new version of an ingestible capsule is designed to improve localization, thereby providing doctors with more precision in locating disease in the small intestine. The new "camera pill” was introduced during the Digestive Disease Week medical conference in San Francisco (CA, USA).

Called M2A Plus, the new version is built on the same platform technology as the M2A capsule endoscope developed by Given Imaging, Ltd. (Yoqneam, Israel) and is supported by new software recently cleared by the US Food and Drug Administration (FDA). Together the capsule and the software, called Rapid, create a graphic representation of a patient's gastrointestinal tract to pinpoint the exact location of a detected pathology. In a validation study involving 92 patients, the capsule location as determined by the Rapid software was successfully matched to the actual location found by fluoroscopy.

"The M2A Plus capsule was developed in direct response to gastroenterologists who expressed their need for a localization capability,” said Dr. Gavriel D. Meron, CEO and president of Given Imaging. "The localization feature is the first of several developments that will enhance physicians' diagnostic capabilities.”




Related Links:
Given Imaging